About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Cancer Biotherapy and Radiopharmaceuticals
›
top-articles
Cancer Biotherapy and Radiopharmaceuticals
2.8
(top 20%)
impact factor
2.1K
(top 10%)
papers
33.1K
(top 10%)
citations
65
(top 10%)
h
-index
2.9
(top 20%)
impact factor
2.3K
all documents
34.7K
doc citations
92
(top 10%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs
Cancer Biotherapy and Radiopharmaceuticals
1997
350
2
Copper-64 Radiopharmaceuticals for PET Imaging of Cancer: Advances in Preclinical and Clinical Research
Cancer Biotherapy and Radiopharmaceuticals
2009
302
3
Growing Applications of “Click Chemistry” for Bioconjugation in Contemporary Biomedical Research
Cancer Biotherapy and Radiopharmaceuticals
2009
254
4
Affinity and Avidity in Antibody-Based Tumor Targeting
Cancer Biotherapy and Radiopharmaceuticals
2009
185
5
A Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti αvβ3) Antibody in Patients with Metastatic Cancer
Cancer Biotherapy and Radiopharmaceuticals
2001
172
6
Structure and Function of Bone Marrow Hemopoiesis: Mechanisms of Response to Ionizing Radiation Exposure
Cancer Biotherapy and Radiopharmaceuticals
2002
169
7
Results of Individual Patient Dosimetry in Peptide Receptor Radionuclide Therapy with
177
Lu DOTA-TATE and
177
Lu DOTA-NOC
Cancer Biotherapy and Radiopharmaceuticals
2007
155
8
Comparison of a Monomeric and Dimeric Radiolabeled RGD-Peptide for Tumor Targeting
Cancer Biotherapy and Radiopharmaceuticals
2002
153
9
Paclitaxel (Taxol): An Inhibitor of Angiogenesis in a Highly Vascularized Transgenic Breast Cancer
Cancer Biotherapy and Radiopharmaceuticals
1999
145
10
Phase I-II Study of Radiopeptide
177
Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors
Cancer Biotherapy and Radiopharmaceuticals
2012
144
11
Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and Radiation
Cancer Biotherapy and Radiopharmaceuticals
1999
136
12
Feasibility of Dosimetry-Based High-Dose 131I-Meta-Iodobenzylguanidine with Topotecan as a Radiosensitizer in Children with Metastatic Neuroblastoma
Cancer Biotherapy and Radiopharmaceuticals
2005
132
13
Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)
Cancer Biotherapy and Radiopharmaceuticals
2010
129
14
Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors
Cancer Biotherapy and Radiopharmaceuticals
2010
125
15
Cancer Immunotherapy
Cancer Biotherapy and Radiopharmaceuticals
2011
120
16
Pre-Targeted Locoregional Radioimmunotherapy with 90Y-biotin in Glioma Patients: Phase I Study and Preliminary Therapeutic Results
Cancer Biotherapy and Radiopharmaceuticals
2001
115
17
Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis
Cancer Biotherapy and Radiopharmaceuticals
2009
113
18
Long-Lived Positron Emitters Zirconium-89 and Iodine-124 for Scouting of Therapeutic Radioimmunoconjugates with PET
Cancer Biotherapy and Radiopharmaceuticals
2003
111
19
Receptor-Binding, Biodistribution, and Metabolism Studies of
64
Cu-DOTA-Cetuximab, a PET-Imaging Agent for Epidermal Growth-Factor Receptor-Positive Tumors
Cancer Biotherapy and Radiopharmaceuticals
2008
111
20
Positron Emission Tomography (PET) for Staging of Solitary Plasmacytoma
Cancer Biotherapy and Radiopharmaceuticals
2003
110
21
Pretargeted Radioimmunotherapy (PRIT™) for Treatment of Non-Hodgkin's Lymphoma (NHL): Initial Phase I/II Study Results
Cancer Biotherapy and Radiopharmaceuticals
2000
109
22
Slow Internalization of Anti-HER2 Synthetic Affibody Monomer
111
In-DOTA-Z
HER2:342-pep2
: Implications for Development of Labeled Tracers
Cancer Biotherapy and Radiopharmaceuticals
2008
108
23
Pharmacokinetics and Imaging of
212
Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients
Cancer Biotherapy and Radiopharmaceuticals
2014
106
24
Inhibition of Growth and Metastasis of Human Pancreatic Cancer Growing in Nude Mice by PTK 787/ZK222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases
Cancer Biotherapy and Radiopharmaceuticals
2001
105
25
The Radioprotective Effect of
Zataria multiflora
Against Genotoxicity Induced by γ Irradiation in Human Blood Lymphocytes
Cancer Biotherapy and Radiopharmaceuticals
2011
104
26
Abscopal Regression of Antigen Disparate Tumors by Antigen Cascade After Systemic Tumor Vaccination in Combination with Local Tumor Radiation
Cancer Biotherapy and Radiopharmaceuticals
2012
101
27
Acquired Cisplatin Resistance in Human Lung Adenocarcinoma Cells Is Associated with Enhanced Autophagy
Cancer Biotherapy and Radiopharmaceuticals
2010
100
28
Peptide Receptor Radionuclide Therapy: An Overview
Cancer Biotherapy and Radiopharmaceuticals
2015
97
29
α-Particle Radioimmunotherapy of Disseminated Peritoneal Disease Using a 212Pb-Labeled Radioimmunoconjugate Targeting HER2
Cancer Biotherapy and Radiopharmaceuticals
2005
95
30
Rhenium-188 - A Generator-Derived Radioisotope for Cancer Therapy
Cancer Biotherapy and Radiopharmaceuticals
1998
94
31
Receptor Radionuclide Therapy with 90Y-DOTATOC in Patients with Medullary Thyroid Carcinomas
Cancer Biotherapy and Radiopharmaceuticals
2004
94
32
Production of [
211
At]-Astatinated Radiopharmaceuticals and Applications in Targeted α-Particle Therapy
Cancer Biotherapy and Radiopharmaceuticals
2013
94
33
The Radiobiology of Conventional Radiotherapy and Its Application to Radionuclide Therapy
Cancer Biotherapy and Radiopharmaceuticals
2005
93
34
Immuno-Positron Emission Tomography: Shedding Light on Clinical Antibody Therapy
Cancer Biotherapy and Radiopharmaceuticals
2010
93
35
Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives
Cancer Biotherapy and Radiopharmaceuticals
2017
93
36
Induction of CA125-Specific B and T Cell Responses in Patients Injected with MAb-B43.13—Evidence for Antibody-Mediated Antigen-Processing and Presentation of CA125 in Vivo
Cancer Biotherapy and Radiopharmaceuticals
2001
92
37
Inhibition of Cell Growth in Culture by Quinones
Cancer Biotherapy and Radiopharmaceuticals
1998
90
38
Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches
Cancer Biotherapy and Radiopharmaceuticals
2018
89
39
FDG-PET in Adrenocortical Carcinoma
Cancer Biotherapy and Radiopharmaceuticals
2001
88
40
Eugenol Enhances the Chemotherapeutic Potential of Gemcitabine and Induces Anticarcinogenic and Anti-inflammatory Activity in Human Cervical Cancer Cells
Cancer Biotherapy and Radiopharmaceuticals
2011
88
41
In Vitro Characterization of a Bivalent Anti-HER-2 Affibody with Potential for Radionuclide-Based Diagnostics
Cancer Biotherapy and Radiopharmaceuticals
2005
87
42
Radiolabeling of Extracellular Vesicles with
99m
Tc for Quantitative
In Vivo
Imaging Studies
Cancer Biotherapy and Radiopharmaceuticals
2016
86
43
Selective Internal Radiation Therapy with SIR-Spheres® in Patients with Nonresectable Liver Tumors
Cancer Biotherapy and Radiopharmaceuticals
2005
84
44
Anticancer Activity and Molecular Mechanism of Resveratrol–Bovine Serum Albumin Nanoparticles on Subcutaneously Implanted Human Primary Ovarian Carcinoma Cells in Nude Mice
Cancer Biotherapy and Radiopharmaceuticals
2010
83
45
Attenuated
Salmonella typhimurium
Containing Interleukin-2 Decreases MC-38 Hepatic Metastases: A Novel Anti-tumor Agent
Cancer Biotherapy and Radiopharmaceuticals
1996
82
46
Low-dose, Fractionated Radioimmunotherapy for B-cell Malignancies using131I-LYM-1 Antibody
Cancer Biotherapy and Radiopharmaceuticals
1998
82
47
Heterodimeric Bispecific Single-Chain Variable-Fragment Antibodies Against EpCAM and CD16 Induce Effective Antibody-Dependent Cellular Cytotoxicity Against Human Carcinoma Cells
Cancer Biotherapy and Radiopharmaceuticals
2013
81
48
NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study
Cancer Biotherapy and Radiopharmaceuticals
2015
80
49
Radionuclide Therapy with Iodine-125 and Other Auger–Electron-Emitting Radionuclides: Experimental Models and Clinical Applications
Cancer Biotherapy and Radiopharmaceuticals
2003
76
50
Design, Synthesis, and Evaluation of Radiolabeled Integrin αvβ3 Receptor Antagonists for Tumor Imaging and Radiotherapy
Cancer Biotherapy and Radiopharmaceuticals
2003
76
site/software ©
exaly
; All materials licenced under
CC by-SA
.